Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: EI 546; Elaspol; LY 544349; ONO 5046; ONO 5046 . Na; ONO 5406; ONO 5406 . Na

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Class Amino acids; Antiasthmatics; Antineoplastics; Antirheumatics; Sulfonamides
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lung injury
  • Discontinued Adult respiratory distress syndrome; Lung disorders; Lung transplant rejection; Non-small cell lung cancer; Pulmonary fibrosis; Respiratory insufficiency; Rheumatoid arthritis

Most Recent Events

  • 13 May 2010 Discontinued - Phase-II for Respiratory insufficiency in Japan (unspecified route)
  • 30 Oct 2009 Sivelestat is still in phase II trials for respiratory insufficiency in Japan
  • 20 Dec 2006 Launched for Acute lung injury in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top